FDA Label Changes for Testosterone Products Remove Heart Risk Warnings

A Major Regulatory Shift

The U.S. Food and Drug Administration (FDA) officially updated the class-wide labelling for all testosterone replacement therapy (TRT) products. The most significant change was the removal of the Boxed Warning — the highest level of safety alert — regarding an increased risk of heart attacks and strokes. This warning had been a feature of TRT packaging since 2015, following smaller, controversial studies that suggested a link between testosterone and cardiovascular events.

The FDA's decision was primarily driven by the results of the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men). This large, multi-year study followed over 5,200 men with confirmed hypogonadism who also had pre-existing cardiovascular risk factors. The results, published in the New England Journal of Medicine, found no statistically significant difference in major adverse cardiovascular events between men taking testosterone and those on a placebo.

A New Standard of Safety for Men

For a decade, the Boxed Warning acted as a deterrent for many men and their physicians, leading to undertreatment of symptomatic low testosterone. Hypogonadism is associated with a range of health issues, including decreased libido, erectile dysfunction, loss of bone density, and increased body fat. The FDA's update acknowledges that, for men with pathological hypogonadism, the therapy is safe when administered and monitored correctly.

However, the updated labelling is not a signal for indiscriminate use. The FDA introduced new requirements including mandatory blood pressure monitoring — as TRT can cause modest increases in blood pressure — and maintained its stance that TRT is indicated only for men with hypogonadism associated with structural or genetic medical conditions, not for age-related declines in testosterone that occur naturally.

Expert Reaction

"This update brings the regulatory landscape in line with modern clinical evidence," said Dr. Mohit Khera, a leading urologist and researcher in male hormones. "We can now treat men who have both low testosterone and cardiovascular concerns with much greater confidence. The focus has shifted from a fear of heart attacks to a more nuanced management of blood pressure and red blood cell counts, which are the real, manageable risks of therapy."